1. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis 
Konstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Sophie Tops, Karolien Claes, Gert Van Assche, Paul Rutgeerts, Severine Vermeire, Marc Ferrante 
Clinical Gastroenterology and Hepatology 
Volume 14, Issue 4, Pages (April 2016)
DOI: /j.cgh
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1 Flowchart of the study population.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
ROC analysis for infliximab serum concentrations at week 2 (A), week 6 (B), and week 14 (C) stratifying patients with and without STMH.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

4. Figure 3
Distribution of serum infliximab concentrations during induction therapy on the basis of STMH. Gray boxes represent infliximab serum concentrations of patients with STMH, and white boxes represent infliximab serum concentrations of patients without STMH. Box plots (5%–95%) show the median (solid line within box), IQR (upper and lower box boundaries), standard deviation (whiskers), and outliers (black dot) (A). Rates of STMH by infliximab serum concentration quartiles at weeks 2, 6, and 14 (P values indicate comparison across quartiles, χ2 test (linear-by-linear association) (B). w, week.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

5. Figure 4
Total infliximab exposure of patients with and without STMH. Average infliximab concentrations for UC patients with or without STMH are represented by (■) and (•), respectively, and 95% CIs are represented by the red and black dotted lines, respectively.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions